Search
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalFDA approved on February 8, 2013.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexProducts: POMALYST® 4 MG, POMALYST 4 MGAtropine
go.drugbank.com/drugs/DB00572ApprovedInvestigationalVet approvedIt is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active. … [A251660] Atropine is a relatively inexpensive drug and is included in the World Health Organization List of Essential Medicines.[A251675]
Mixtures: LOMOTİL 2,5 MG + 0,025 MG / 5 ML ORAL ÇÖZELTİ, 60 ML, B-DonnaCategories: P-glycoprotein substratesANA975
go.drugbank.com/drugs/DB06490ExperimentalANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.
Synonyms: ((2R,3R,4R,5R)-4-ACETOXY-5-(5-AMINO-2-OXO-THIAZOLO(4,5-D)PYRIMIDIN-3-YL)-2-(HYDROXYMETHYL)TETRAHYDROFURAN-3-YL) ACETATE, THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-Lornoxicam
go.drugbank.com/drugs/DB06725ApprovedInvestigationalLornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. … Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties.
Mixtures: LORNOPAR 8/300 MG EFERVESAN TABLET ,20 ADETCategories: Non COX-2 selective NSAIDS, Cytochrome P-450 SubstratesEtelcalcetide
go.drugbank.com/drugs/DB12865ApprovedInvestigationalEtelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. … Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Products: PARSABİV 5 MG/1 ML I.V. ENJEKSİYONLUK ÇÖZELTİ, 6 ADET, PARSABİV 10 MG/2 ML I.V. ENJEKSİYONLUK ÇÖZELTİ, 6 ADETBenzoyl peroxide
go.drugbank.com/drugs/DB09096ApprovedInvestigationalBenzoyl peroxide is a commonly used drug in topical treatments for acne. … [A234059,A234064,A234069] Benzoyl peroxide, in combination with erythromycin, was granted FDA approval on 26 October 1984.[L33264]
Mixtures: OXIMIN 10 MG/G + 50 MG/G JEL,50 G, OXIMIN 10 MG/G + 50 MG/G JEL,25 GProducts: Bpo 6%, BPO 6 FoamingBudesonide
go.drugbank.com/drugs/DB01222ApprovedInvestigational[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994.[L10598] It is also available in a combination product with [formoterol].[L10619] … Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Mixtures: BUDEK PLUS® 200/6 MCG, POENA 4/400 MCG INHALASYON IÇIN TOZ IÇEREN BLISTER ,60 DOZCategories: P-glycoprotein substrates, Cytochrome P-450 SubstratesMethotrimeprazine
go.drugbank.com/drugs/DB01403ApprovedA phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine.
Categories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsSynonyms: (-)-(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine, (-)-10-(3-(Dimethylamino)-2-methylpropyl)-2-methoxyphenothiazine2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
go.drugbank.com/bio_entities/BE0001450TargetEscherichia coli (strain K12)Catalyzes the transfer of pyrophosphate from adenosine triphosphate (ATP) to 6-hydroxymethyl-7,8-dihydropterin, an enzymatic step in folate biosynthesis pathway.
Polypeptides: 2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinaseSynonyms: 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase, 7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinaseZilebesiran
go.drugbank.com/drugs/DB18929InvestigationalAntihypertensive Medications (KARDIA-3)). … Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
Synonyms: - triazanonacosan-29-oyl}-4-hydroxypyrrolidin-, (2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2- acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17